157 related articles for article (PubMed ID: 36482811)
21. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
22. [Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
Matte P; Campedel L
Bull Cancer; 2022; 109(7-8):738-740. PubMed ID: 35606195
[No Abstract] [Full Text] [Related]
23. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
Zhu X; Koshkin VS
Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
[TBL] [Abstract][Full Text] [Related]
24. Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
Sonpavde GP; Sternberg CN; Loriot Y; Marabelle A; Lee JL; Fléchon A; Roubaud G; Pouessel D; Zagonel V; Calabro F; Banna GL; Shin SJ; Vera-Badillo FE; Powles T; Hellmis E; Miranda PAP; Lima AR; Emeribe U; Oh SM; Hotte SJ
Eur J Cancer; 2022 Mar; 163():55-65. PubMed ID: 35042068
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
[TBL] [Abstract][Full Text] [Related]
26. The future of drug development in urothelial cancer.
Dreicer R
J Clin Oncol; 2012 Feb; 30(5):473-5. PubMed ID: 22184400
[No Abstract] [Full Text] [Related]
27. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
28. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
29. Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
Furubayashi N; Morokuma F; Tomoda T; Hori Y; Negishi T; Miura A; Komori H; Kuroiwa K; Nakamura M
Anticancer Res; 2022 Mar; 42(3):1571-1577. PubMed ID: 35220254
[TBL] [Abstract][Full Text] [Related]
30. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
[TBL] [Abstract][Full Text] [Related]
31. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE
Future Oncol; 2024 Mar; 20(7):351-360. PubMed ID: 37994649
[TBL] [Abstract][Full Text] [Related]
32. Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases.
Sugihara Y; Kawai T; Yamada D; Furuyama C; Sato Y; Kume H
Eur J Cancer; 2020 Feb; 126():91-92. PubMed ID: 31923731
[No Abstract] [Full Text] [Related]
33. Ramucirumab plus docetaxel for urothelial carcinoma.
Baker H
Lancet Oncol; 2016 Apr; 17(4):e140. PubMed ID: 26973322
[No Abstract] [Full Text] [Related]
34. Editorial Comment to "The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion".
Kikuchi E; Hayakawa N
Int J Urol; 2023 Sep; 30(9):786-787. PubMed ID: 37461821
[No Abstract] [Full Text] [Related]
35. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report.
Hunter L; Moser J; Sturge C; Barraza G; Colonna S
J Oncol Pharm Pract; 2020 Jan; 26(1):216-219. PubMed ID: 30832555
[TBL] [Abstract][Full Text] [Related]
36. Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
Bellmunt J; Chang J; Pavilack-Kirker M; Cappelleri JC; Costa N; Esterberg E; Kearney M; Hitchens A; Candrilli SD; Ajmera M
Clin Genitourin Cancer; 2023 Aug; 21(4):459-466. PubMed ID: 37149458
[TBL] [Abstract][Full Text] [Related]
37. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T;
Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Hale O; Patterson K; Lai Y; Meng Y; Li H; Godwin JL; Homet Moreno B; Mamtani R
Clin Genitourin Cancer; 2021 Feb; 19(1):e17-e30. PubMed ID: 32826180
[TBL] [Abstract][Full Text] [Related]
39. Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
Dang E; Vallée A; Lepage-Seydoux C; Sejean K; Bonan B; Abraham C; Beuzeboc P; Ratta R
Curr Oncol; 2022 Feb; 29(2):945-955. PubMed ID: 35200579
[TBL] [Abstract][Full Text] [Related]
40. The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract.
de Mulder PH; Sternberg CN; van Oosterom AT; Fossa SD
Semin Oncol; 1994 Feb; 21(1 Suppl 1):65-9. PubMed ID: 7512278
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
